La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
ACADIA Pharmaceuticals Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Steve Davis
Amministratore delegato
US$7.6m
Compenso totale
| Percentuale dello stipendio del CEO | 11.3% |
| Mandato del CEO | 9yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 8.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$31m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$8m | US$857k | -US$61m |
| Sep 30 2023 | n/a | n/a | -US$149m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$14m | US$822k | -US$216m |
| Sep 30 2022 | n/a | n/a | -US$217m |
| Jun 30 2022 | n/a | n/a | -US$205m |
| Mar 31 2022 | n/a | n/a | -US$214m |
| Dec 31 2021 | US$10m | US$793k | -US$168m |
| Sep 30 2021 | n/a | n/a | -US$192m |
| Jun 30 2021 | n/a | n/a | -US$262m |
| Mar 31 2021 | n/a | n/a | -US$260m |
| Dec 31 2020 | US$8m | US$768k | -US$282m |
| Sep 30 2020 | n/a | n/a | -US$268m |
| Jun 30 2020 | n/a | n/a | -US$225m |
| Mar 31 2020 | n/a | n/a | -US$238m |
| Dec 31 2019 | US$8m | US$744k | -US$235m |
| Sep 30 2019 | n/a | n/a | -US$248m |
| Jun 30 2019 | n/a | n/a | -US$268m |
| Mar 31 2019 | n/a | n/a | -US$276m |
| Dec 31 2018 | US$7m | US$720k | -US$245m |
| Sep 30 2018 | n/a | n/a | -US$249m |
| Jun 30 2018 | n/a | n/a | -US$252m |
| Mar 31 2018 | n/a | n/a | -US$256m |
| Dec 31 2017 | US$15m | US$700k | -US$289m |
Compensazione vs Mercato: La retribuzione totale di Steve ($USD 7.59M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Steve Davis (63 yo)
9yrs
Mandato
US$7,587,014
Compensazione
Mr. Stephen R. Davis, also known as Steve, J. D. served as the Director at Heron Therapeutics Inc. since September 2019 until February 21, 2023. He has been the Chief Executive Officer of ACADIA Pharmaceut...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 9yrs | US$7.59m | 0.11% $ 2.9m | |
| Executive VP & CFO | 3yrs | US$2.59m | 0.026% $ 686.3k | |
| Executive VP | 2.8yrs | US$2.62m | 0.031% $ 818.8k | |
| VP, Chief Accounting Officer & Corporate Controller | 4.1yrs | Nessun dato | 0.0087% $ 225.4k | |
| Executive VP and Head of Research & Development | less than a year | Nessun dato | Nessun dato | |
| Senior Vice President of Technical Development & Operations | 1.8yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Investor Relations & Corporate Communications | less than a year | Nessun dato | Nessun dato | |
| Executive VP | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Head of Sales | 2.7yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief People Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Senior Vice President of New Product Planning & Strategy | no data | Nessun dato | Nessun dato | |
| SVP, Global Head of Medical Affairs & Chief Medical Officer | 4.8yrs | Nessun dato | Nessun dato |
2.7yrs
Durata media
52yo
Età media
Gestione esperta: Il team dirigenziale di ACAD è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 9yrs | US$7.59m | 0.11% $ 2.9m | |
| Independent Director | 16.3yrs | US$392.75k | 0.012% $ 316.2k | |
| Independent Director | 8.8yrs | US$377.75k | 0.062% $ 1.6m | |
| Member of the Scientific and Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 8.8yrs | US$387.75k | 0.015% $ 402.6k | |
| Independent Director | 9.5yrs | US$387.75k | 0.021% $ 543.7k | |
| Member of the Scientific and Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific and Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of the Scientific and Clinical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 8.7yrs | US$387.75k | 0.015% $ 386.7k | |
| Independent Chairman of the Board | 11.7yrs | US$432.75k | 0.062% $ 1.6m | |
| Independent Director | 4yrs | US$377.75k | 0.014% $ 353.2k |
8.9yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ACAD sono considerati esperti (durata media dell'incarico 8.8 anni).